E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
No medical condition or disease involved. The study subjects are healthy volunteers. |
|
E.1.1.1 | Medical condition in easily understood language |
Not applicable. Healthy volunteers will be studied. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of this study is to reveal what happens in the brain when consciousness is impaired during sleep and during anesthetic-induced sedation, which brain structures are responsible for the most primitive conscious state and what makes our rich conscious experiences possible. Finding tools for the distinction of consciousness, connectedness and responsiveness would be groundbreaking and would represent a major leap forward in the study of human consciousness. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Healthy male volunteers will be considered eligible for the study.
The subjects must meet all of the following criteria:
1. Male
2. Age 20–30 years
3. Good general health i.e. American Society of Anesthesiologists (ASA) physical status I
4. Fluent in Finnish language
5. Right handedness
6. Written informed consent
7. Good sleep quality |
|
E.4 | Principal exclusion criteria |
The subject must be excluded if any of the following criteria are met:
1. Chronic medication
2. History of alcohol and/or drug abuse
3. Strong susceptibility for allergic reactions
4. Serious nausea in connection with previous anesthesia
5. Strong susceptibility for nausea
6. Any use of drugs or alcohol during the 48 hours preceding anesthesia
7. Use of caffeine products 10–12 hours prior the study, 24 hours before sleep studies
8. Smoking
9. Clinically significant previous cardiac arrhythmia / cardiac conduction impairment
10. Clinically significant abnormality in prestudy laboratory tests
11. Positive result in the drug screening test
12. Blood donation within 90 days prior to the study
13. Participation in any medical study with an experimental drug or device during the preceding 60
days
14. The study subject has undergone a prior PET or SPECT study
15. Any contraindication to magnetic resonance imaging (MRI)
16. Hearing impairment
17. Detected unsuitability based on initial electrophysiological measurements (Parts 2–5)
18. Detected unsuitability based on MRI scanning results (Parts 3–6)
19. Sleep disorder or severe sleep problem |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Due to the exploratory nature of the study no primary variables are defined. This is explained and justified in the study protocol. Analysis of PET and other data is described in detail in section 11.
During the study, a series of Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI) and electroencephalography (EEG) studies will be carried out on 200–240 healthy male subjects to reveal the neural correlates of consciousness. Consciousness of the subjects will be manipulated with normal sleep and anesthetic agents dexmedetomidine acting through α2-agonism, with propofol and sevoflurane both mainly acting through the enhancement of gamma-aminobutyric acid (GABA) system, and with S-ketamine acting through N-methyl-D-aspartate (NMDA) receptor antagonism.
The study consists of six (6) parts. First, various neurophysiological tools to separate consciousness, connectedness and responsiveness during normal sleep will be tested in Part 1. The most suitable methods and subjects will be selected and then tested during anesthetic-induced sedation and loss of responsiveness (LOR) in Part 2. The anesthetics (dexmedetomidine or propofol) will be administered as target-controlled infusions (TCI) with step-wise concentration-increments at 10–20
min intervals until LOR is detected in 40 (20 for dexmedetomidine and 20 for propofol) subjects. In Part 3, the TCIs are repeated in the same 40 subjects but adjusted according to the individual drug
target concentrations sufficient for LOR, and a series of PET perfusion imaging measurements will be performed to obtain the brain activity information in various states of consciousness. Based on the experiences from Part 1 and 2, the most promising neurophysiological tools will be applied during the imaging session. In Part 4, the same 40 subjects who participated in Parts 2 and 3 will be imaged with PET for brain activity after sleep deprivation (awake), after falling asleep (sleep onset NREM stage 1), during light (NREM stage 2) sleep, during deep (slow-wave, NREM stage 3) sleep and immediately after awakening. In Part 5, 10 dexmedetomidine subjects who participated in Parts 2–4
will be given the drug once more, and functional MRI (fMRI) data will be collected at various states of consciousness before and during verbal and nonverbal vocalizations. In Part 6, a separate set of
160 subjects will be recruited to receive EC50 concentration of dexmedetomidine or propofol (40 subjects/drug) while being imaged for cerebral metabolic rate of
glucose (CMRglu). EEG will be continuously collected in all sessions (Parts 1–6). The depth of anesthesia will be measured using quantitative EEG and bispectral index (BIS) monitoring. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Multiple time points. See E.5.1. |
|
E.5.2 | Secondary end point(s) |
Not applicable. See E.5.1. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
not applicable. See E.5.1. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
The explanation of consciousness poses one of the greatest challenges to science and philosophy in the 21st century. It remains unclear what consciousness is and how it emerges from brain activity. By studying anesthesia and sleep, we aim to reveal what happens in the brain when consciousness is lost and when it returns. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
The study is partly randomized. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Anesthesia will be compared to natural sleep. |
|
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |